title: FGFR3 mutations and the skin: report of a patient with a FGFR3 gene mutation, acanthosis nigricans, hypochondroplasia and hyperinsulinemia and review of the literature.
abstract: Fibroblast growth factor receptor 3 (FGFR3) gene mutations in the germline are well-known causes of skeletal syndromes. Somatic FGFR3 mutations have been found in malignant neoplasms and more recently in several cutaneous elements. We present a 14-year-old girl with mild hypochondroplasia who developed acanthosis nigricans. The report of a K650Q mutation in the FGFR3 gene in a similar case prompted us to conduct a point mutation analysis. The K650Q mutation was confirmed, but in contrast to the previous case, we additionally report findings of hyperinsulinemia. In the recent literature, an increasing number of different cutaneous elements have been found to harbor mutations of FGFR3, suggesting that FGFR3 plays a role in the pathogenesis of these elements. We review the present literature, describing studies in which FGFR3 mutations have been investigated in skin lesions: primarily seborrheic keratoses and epidermal nevi, but also other benign skin tumors and a single case of a squamous cell carcinoma. In addition, an overview of the FGFR3 point mutations in relation to each cutaneous element is given. Based on the current knowledge, it seems likely that these cutaneous lesions have a common genetic background. Our case shows that FGFR3 mutation analysis should be considered in case of the coexistence of acanthosis nigricans and a skeletal dysplasia. Testing for hyperinsulinemia is essential, also if a gene mutation is confirmed.
authors.affiliation: Department of Dermato-Allergology, Gentofte Hospital, Copenhagen, Denmark. Maria@Blombergs.dk
authors.forename: M
authors.initials: M
authors.lastname: Blomberg
authors.forename: E M
authors.initials: EM
authors.lastname: Jeppesen
authors.forename: F
authors.initials: F
authors.lastname: Skovby
authors.forename: E
authors.initials: E
authors.lastname: Benfeldt
mesh_terms: D000052:Acanthosis Nigricans / Q000175:diagnosis / Q000235:genetics* / Q000473:pathology; D000293:Adolescent; D001786:Blood Glucose / Q000187:drug effects; D002096:C-Peptide / Q000097:blood; D004392:Dwarfism / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000627:therapeutic use; D019382:Human Growth Hormone / Q000627:therapeutic use; D006801:Humans; D006946:Hyperinsulinism / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics*; D017492:Keratosis, Seborrheic / Q000235:genetics; D008687:Metformin / Q000627:therapeutic use; D017354:Point Mutation; D051498:Receptor, Fibroblast Growth Factor, Type 3 / Q000235:genetics*
chemical_list: D001786:Blood Glucose; D002096:C-Peptide; D019382:Human Growth Hormone; D007987:Gonadotropin-Releasing Hormone; D008687:Metformin; C496365:FGFR3 protein, human; D051498:Receptor, Fibroblast Growth Factor, Type 3